1. Sub-Segment: Biopharmaceuticals
Biopharmaceuticals are a key sub-segment within the plant-based biologics market. These are pharmaceutical products derived from plant sources used for treating various diseases and medical conditions. The use of plant-based biopharmaceuticals offers several advantages, including reduced production costs, scalability, and lower environmental impact compared to traditional pharmaceuticals.
The demand for plant-based biopharmaceuticals is growing rapidly, primarily driven by the increasing prevalence of chronic diseases, the need for cost-effective treatment options, and the rising adoption of plant-based medicines among healthcare professionals and patients. Additionally, advancements in biotechnology and genetic engineering have enabled the production of highly efficient and targeted plant-based biopharmaceuticals.
The plant-based biologics market is highly competitive and fragmented, with several key players operating globally. These players are focusing on research and development activities, strategic collaborations, and mergers and acquisitions to gain a competitive advantage.
Some of the prominent players in the market include: Zea Biosciences, Mapp Biopharmaceutical,, Ventria Bioscience, IBIO,, plantform corporation, Planet Biotechnology, Leaf Expression Systems, Medicago, Eleva GmbH, InVitria.
These companies are continuously investing in innovative technologies and product development to expand their market presence and cater to the increasing demand for plant-based biologics. Additionally, the market is witnessing the entry of new players, further intensifying the competition.